Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT04305379 Terminated - Prostate Cancer Clinical Trials

Augmented BLAdder NecK rEconstruction Trial for Improved Urinary Function After Radical Prostatectomy

BLANKET
Start date: January 16, 2020
Phase: N/A
Study type: Interventional

The investigators are conducting a prospective, randomized trial to investigate whether patients randomized to receive an augmented bladder neck reconstruction (aBNR) at the time of robotic-assisted laparoscopic prostatectomy experience improved urinary function post-operatively compared to patients who undergo prostatectomy with a standard BNR. An aBNR here consists of the autologous medial umbilical ligament sling as well as a bladder neck intussusception stitch. The standard BNR group will receive the intussusception stitch only.

NCT ID: NCT04266262 Terminated - Prostate Cancer Clinical Trials

High-Intensity Training for Men With Prostate Cancer on Active Surveillance: A Feasibility Study

Start date: July 9, 2018
Phase: N/A
Study type: Interventional

This is a randomized study aiming to assess the feasibility of a phase II randomized controlled trial of different high-intensity training interventions and usual care (UC) in men with prostate cancer (PCa) undergoing active surveillance (AS).

NCT ID: NCT04221828 Terminated - Prostate Cancer Clinical Trials

Trial of NanoPac Focal Therapy for Prostate Cancer

Start date: October 20, 2020
Phase: Phase 2
Study type: Interventional

This study evaluates the use of NanoPac injected directly into the prostate lesion in men with prostate cancer.

NCT ID: NCT03927924 Terminated - Prostate Cancer Clinical Trials

High-intensity Focused Ultrasound Study

Start date: June 25, 2019
Phase: N/A
Study type: Interventional

Conventional treatment options for localized prostate cancer include prostatectomy, radiotherapy and active surveillance. However, prostatectomy and radiotherapy carry certain degree of morbidity, including the risks of urinary incontinence, erectile dysfunction and injury to the structures in the proximity. Active surveillance carries the risk of disease progression and psychological distress to the patients. Focal therapy employs the concept of only destroying the significant lesion, resulting in disease cure and improved functional outcome. Among the different options of focal therapy, high-intensity focused ultrasound (HIFU) is one of the most commonly employed energy sources. It exerts its effect through thermal and mechanical destruction of cancer tissue. This study aims at assess the effectiveness of such treatment in prostate cancer management. In this study, investigators evaluate the early oncological outcome and objective functional outcome of patients undergoing HIFU for the treatment of localized intermediate risk prostate cancer.

NCT ID: NCT03886493 Terminated - Prostate Cancer Clinical Trials

Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer

Start date: August 28, 2019
Phase: Phase 2
Study type: Interventional

This is a single-center, single arm, open-label phase II study evaluating the safety, anti-tumor effect, and immunogenicity of neoadjuvant Dupixent given prior to radical prostatectomy.

NCT ID: NCT03741712 Terminated - Prostate Cancer Clinical Trials

A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC

Start date: November 20, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this trial is to study the tolerance, pharmacokinetics (PK) and efficacy of SHR2554 alone or in combination with SHR3680 in the treatment of patients with metastatic Castration Resistant Prostate Cancer.

NCT ID: NCT03724253 Terminated - Breast Cancer Clinical Trials

[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)

NeoFIND
Start date: July 3, 2018
Phase: Phase 2
Study type: Interventional

This was a Phase II, multi-center, open label, single dose study in patients with tumor types known to overexpress Gastrin-Releasing Peptide Receptor (GRPR), including breast, prostate, colorectal, Non-Small Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC).

NCT ID: NCT03689582 Terminated - Prostate Cancer Clinical Trials

Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer

Start date: November 13, 2018
Phase: Phase 2
Study type: Interventional

The purpose of the study is to find out whether imaging of the prostate with a new molecule called 68Ga-PSMA can find prostate cancer. 68Ga-PSMA has been shown in a large number of patients to be useful to find recurring prostate cancer following initial cancer treatment. This study is performed to test 68Ga-PSMA whether it can be used to find prostate cancers that would be considered in need for treatment.

NCT ID: NCT03652298 Terminated - Prostate Cancer Clinical Trials

Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative Disease Progression and Partners

NeuroPrevPTSD
Start date: July 25, 2018
Phase: Phase 2
Study type: Interventional

The diagnosis and treatment trajectory of cancer can constitute a traumatic event because these can be perceived as sudden, catastrophic and life threatening. One common mental disorder following traumatic events is post-traumatic stress disorder (PTSD), described as reexperiencing of the event (e.g., having intrusive thoughts), having avoidance of trauma memories, emotional numbing, and experiencing hyperarousal symptoms. To date, and to the best of the investigator's knowledge, few studies have focused on PTSD in advanced cancer, but the existing data show that these patients are at risk for experiencing PTSD symptoms. Among the early interventions for preventing PTSD in people confronted by traumatic events is group debriefing, the retelling of the event, receiving empathy and compassion, and being encouraged to express feelings. However, four meta-analyses found debriefing to be ineffective. A neuroscience-based and evidence-based alternative may be the Memory Structuring Intervention (MSI) that tries to shift trauma processing from a limbic, emotional and somatic level to a frontal-cortical, cognitive and verbal level of processing. The MSI tries to achieve this shift by teaching people confronted with traumatic events to chronologically organize the segments of the event, to verbally label feelings or somatic sensations rather than re-experience them, and to provide causal links between the event's segments and causality to their feelings and sensations Since in males, sympathetic responses were more predictive of PTSD than in females , parasympathetic activation may be needed to be added to the MSI, for men. A main branch of the parasympathetic response is the vagus nerve, whose non-invasive index is Heart Rate Variability (HRV). One way to increase HRV, and thus parasympathetic activation, is through vagal breathing (i.e., deep, paced breathing). Therefore, adding to the MSI deep vagal breathing (VB) to reduce sympathetic hyperactivity, may increase connectivity between the amygdala and the frontal cortex. This may also increase the emotional regulation possibly yielded by the MSI, however in both genders. The effects of the MSI + vagal breathing on PTSD symptoms and on prognosis in advanced cancer patients receiving announcement of terminal cancer have never been investigated. Furthermore, whether reduced inflammation and increased emotional regulation may account for such effects needs to be investigated at the fundamental level. This project reflects the merging of neuroscience, psychooncology and psychoneuroimmunology for better understanding and treating cancer patients, as well as their partners.

NCT ID: NCT03634579 Terminated - Prostate Cancer Clinical Trials

MRI Guided Prostate Cancer Focal Laser Ablation

Start date: June 1, 2018
Phase: N/A
Study type: Interventional

The study is a prospective, single-arm, non-randomized, unblinded trial to determine the safety and efficacy of MRI guided focal laser ablation of localized low and intermediate risk prostate cancer. All subjects meeting the inclusion exclusion criteria and are enrolled will undergo a MRI guided focal laser ablation procedure. The primary aim of the study is to study the safety and efficacy of the procedure.